WO2008085306A1 - Carbon dioxide absorbent - Google Patents
Carbon dioxide absorbent Download PDFInfo
- Publication number
- WO2008085306A1 WO2008085306A1 PCT/US2007/025659 US2007025659W WO2008085306A1 WO 2008085306 A1 WO2008085306 A1 WO 2008085306A1 US 2007025659 W US2007025659 W US 2007025659W WO 2008085306 A1 WO2008085306 A1 WO 2008085306A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- absorbent
- lithium
- hydroxide
- chloride
- lithium hydroxide
- Prior art date
Links
- 239000002250 absorbent Substances 0.000 title claims abstract description 84
- 230000002745 absorbent Effects 0.000 title claims abstract description 83
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229910002092 carbon dioxide Inorganic materials 0.000 title claims abstract description 36
- 239000001569 carbon dioxide Substances 0.000 title claims abstract description 29
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims abstract description 119
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229910001868 water Inorganic materials 0.000 claims abstract description 39
- 239000002243 precursor Substances 0.000 claims abstract description 31
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims abstract description 27
- 235000011941 Tilia x europaea Nutrition 0.000 claims abstract description 27
- 239000004571 lime Substances 0.000 claims abstract description 27
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 41
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 238000009472 formulation Methods 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 29
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 28
- 239000001110 calcium chloride Substances 0.000 claims description 28
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 28
- 206010002091 Anaesthesia Diseases 0.000 claims description 16
- 230000037005 anaesthesia Effects 0.000 claims description 16
- 239000003906 humectant Substances 0.000 claims description 14
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 14
- 229960002078 sevoflurane Drugs 0.000 claims description 13
- PAZHGORSDKKUPI-UHFFFAOYSA-N lithium metasilicate Chemical compound [Li+].[Li+].[O-][Si]([O-])=O PAZHGORSDKKUPI-UHFFFAOYSA-N 0.000 claims description 10
- 229910052912 lithium silicate Inorganic materials 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 claims description 9
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 claims description 9
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 6
- VXJIMUZIBHBWBV-UHFFFAOYSA-M lithium;chloride;hydrate Chemical compound [Li+].O.[Cl-] VXJIMUZIBHBWBV-UHFFFAOYSA-M 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 4
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 11
- 238000001035 drying Methods 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229960003537 desflurane Drugs 0.000 claims 1
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 claims 1
- 229960000305 enflurane Drugs 0.000 claims 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 claims 1
- 229960003132 halothane Drugs 0.000 claims 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims 1
- 229960002725 isoflurane Drugs 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 abstract description 14
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract description 14
- 239000006227 byproduct Substances 0.000 abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000008188 pellet Substances 0.000 description 12
- 235000011118 potassium hydroxide Nutrition 0.000 description 12
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical group [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 11
- 239000000920 calcium hydroxide Substances 0.000 description 11
- 235000011116 calcium hydroxide Nutrition 0.000 description 10
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- JVICFMRAVNKDOE-UHFFFAOYSA-M ethyl violet Chemical compound [Cl-].C1=CC(N(CC)CC)=CC=C1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 JVICFMRAVNKDOE-UHFFFAOYSA-M 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- -1 hydroxide ions Chemical class 0.000 description 6
- 230000003434 inspiratory effect Effects 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 229910001416 lithium ion Inorganic materials 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229960002337 magnesium chloride Drugs 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZALFXJGMURTKRI-UHFFFAOYSA-N 6-methyl-2-[4-[2-[4-(6-methyl-7-sulfo-1,3-benzothiazol-2-yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonic acid Chemical compound C1=C(C)C(S(O)(=O)=O)=C2SC(C3=CC=C(C=C3)N=NNC3=CC=C(C=C3)C3=NC4=CC=C(C(=C4S3)S(O)(=O)=O)C)=NC2=C1 ZALFXJGMURTKRI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000143957 Vanessa atalanta Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- QHFQAJHNDKBRBO-UHFFFAOYSA-L calcium chloride hexahydrate Chemical group O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2] QHFQAJHNDKBRBO-UHFFFAOYSA-L 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 238000005796 dehydrofluorination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- CZIRZNRQHFVCDZ-UHFFFAOYSA-L titan yellow Chemical compound [Na+].[Na+].C1=C(C)C(S([O-])(=O)=O)=C2SC(C3=CC=C(C=C3)/N=N/NC3=CC=C(C=C3)C3=NC4=CC=C(C(=C4S3)S([O-])(=O)=O)C)=NC2=C1 CZIRZNRQHFVCDZ-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/02—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3007—Moulding, shaping or extruding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/22—Carbon dioxide-absorbing devices ; Other means for removing carbon dioxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/34—Chemical or biological purification of waste gases
- B01D53/46—Removing components of defined structure
- B01D53/62—Carbon oxides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
- B01J20/041—Oxides or hydroxides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
- B01J20/046—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing halogens, e.g. halides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/01—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes specially adapted for anaesthetising
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2251/00—Reactants
- B01D2251/30—Alkali metal compounds
- B01D2251/302—Alkali metal compounds of lithium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2251/00—Reactants
- B01D2251/40—Alkaline earth metal or magnesium compounds
- B01D2251/404—Alkaline earth metal or magnesium compounds of calcium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2251/00—Reactants
- B01D2251/60—Inorganic bases or salts
- B01D2251/606—Carbonates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2257/00—Components to be removed
- B01D2257/50—Carbon oxides
- B01D2257/504—Carbon dioxide
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4533—Gas separation or purification devices adapted for specific applications for medical purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4566—Gas separation or purification devices adapted for specific applications for use in transportation means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/42—Materials comprising a mixture of inorganic materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/46—Materials comprising a mixture of inorganic and organic materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/49—Materials comprising an indicator, e.g. colour indicator, pH-indicator
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02C—CAPTURE, STORAGE, SEQUESTRATION OR DISPOSAL OF GREENHOUSE GASES [GHG]
- Y02C20/00—Capture or disposal of greenhouse gases
- Y02C20/40—Capture or disposal of greenhouse gases of CO2
Definitions
- the present invention relates to a carbon dioxide absorbent formulation for gaseous systems, comprising: lime essentially free of sodium or potassium hydroxides; lithium hydroxide or its precursor; and water.
- the absorbent formulation is specifically intended for use during low-flow or closed-circuit anesthesia, but may be used for any application in which traditional soda lime absorbents are used.
- the most common absorbent for carbon dioxide is hydrated lime, or calcium hydroxide. Water is required in the absorbent formulation to serve as a substrate in the net CO 2 absorption reaction:
- a disadvantage of soda lime is the sensitivity of anesthetic agents to strong hydroxide bases.
- the most commonly used modern anesthetic agents are fluorinated hydrocarbons, which may chemically react with sodium and/or potassium hydroxide to form potentially toxic byproducts.
- the anesthetic sevoflurane (1,1, 1,3,3, 3-hexafluoro-2- (fluoromethoxy)propane) has been found to undergo hydroxide-induced dehydrofluorination to produce a fluoro-olefin byproduct called "Compound A” (fluoromethyl-2,2-difluoro-l- (trifluoromethyl)vinyl ether), which is nephrotoxic to rats at concentrations of 60 to 100 ppm and lethal at concentrations of 350 to 400 ppm.
- Compound A fluoromethyl-2,2-difluoro-l- (trifluoromethyl)vinyl ether
- the first approach is to remove strong alkali hydroxides, such as sodium and potassium hydroxide, from the absorbent formulation.
- U.S. Pat. No 6,228,150 and U.S. Pub. No. 2004/0029730 each disclose a carbon dioxide absorbent comprising calcium hydroxide essentially free of sodium and potassium hydroxide.
- World publication WO 01/45837 discloses a carbon dioxide absorbent comprising lime essentially free of sodium hydroxide, essentially free of water, essentially free of a humectant, and containing at least 20% anhydrous lithium hydroxide.
- German patent publication DE 197 40 736 discloses the use of lime free of sodium hydroxide and potassium hydroxide, to which barium hydroxide and/or magnesium hydroxide and/or lithium hydroxide may be added. No ranges are disclosed in DE 197 40 736, nor is the water content of the formulation. None of the publications listed above disclose the use of 0.1 to 17% lithium hydroxide, any of its precursors, or any combination thereof, with 70 to 90 wt% hydrated lime and 5 to 25 wt% water.
- the second approach used to circumvent anesthetic degradation is the addition of a hygroscopic salt or other humectant to enhance the water retention and/or color indicating properties of the absorbent mixture.
- Canadian patent 1151633 discloses the use of calcium chloride to enhance the water retention properties of soda lime.
- U.S. Pub. No. 2004/0029730 discloses the use of 0.2 to 2.0 wt% calcium chloride and/or magnesium chloride in a soda lime absorbent formulation.
- 6,228,150 discloses a lime-based carbon dioxide formulation which includes an inorganic humectant, wherein the humectant is calcium chloride hexahydrate and/or magnesium chloride hexahydrate, present in an amount sufficient to yield 7.5 to 20 wt% water.
- this publication discloses the addition of 2.5 to 25 vol% of glycerol as an organic humectant. Glycerol is also known to be reactive toward olefin products such as Compound A (Cunningham et al. 1996).
- 6,867,165 discloses a carbon dioxide absorbent comprising calcium hydroxide, which may contain sodium or potassium hydroxide, water, a rheology modifier taken from a group of phosphonic acids and salts, and 0.1 to 6.0 wt% calcium chloride to improve color indication properties. None of the publications listed above disclose the use of calcium chloride or any other humectant in a formulation comprising 0.1 to 17 wt% lithium hydroxide or any of its precursors, or any combination thereof, with 70 to 90 wt% lime and 5 to 25 wt% water.
- the present invention is an absorbent for carbon dioxide comprising: 70 to 90 wt% lime, essentially free of potassium hydroxide and sodium hydroxide; 0.5 to 17 wt% lithium hydroxide, one or more of its precursors, or any combination thereof; and 5 to 25 wt% water.
- Lithium hydroxide precursors are compounds which will release lithium ions in solution, hi the presence of lime (calcium hydroxide) and water, the lithium-bearing compound will release lithium ions along with calcium ions and hydroxide ions, thereby forming in situ, LiOH.
- LiOH precursors include, but are not limited to, anhydrous lithium hydroxide (LiOH), lithium hydroxide monohydrate (LiOH-H 2 O), lithium chloride (LiCl), lithium chloride hydrate (LiCl-H 2 O), lithium carbonate (Li 2 CO 3 ), and lithium silicates.
- the formulation may include hardening agents, moisture indicators, exhausting indicators, or humectants from about 0.1 to 10 wt%.
- the absorbent is granulated and may be used for an application in which soda lime is presently used, such as in submarines, Closed Circuit Underwater Breathing Apparatus, or emergency respiratory apparatus.
- the present invention is intended for use in medical anesthesia, including low-flow and closed-circuit anesthesia, because of its compatibility with inhalational anesthetic agents. Because of the increased activity of lithium hydroxide, the life of the absorbent of the present invention is typically longer than that of other commercial products without additional strong alkali.
- the carbon dioxide absorbent is prepared by mixing the lime, lithium hydroxide or its precursor, and water to form a paste, which is extruded to form granules.
- the granulated material is then dried to the desired water content or completely dried and re-hydrated to the desired water content, and screened to retain pellet sizes between about 2 and 5 mm in diameter.
- Other shapes and sizes of the absortent of the present invention are also contemplated.
- Lithium hydroxide precursors are compounds which will release lithium ions in solution. In the presence of lime (calcium hydroxide) and water, the lithium-bearing compound will release lithium ions along with calcium ions and hydroxide ions, thereby forming in situ, LiOH.
- LiOH precursors include, but are not limited to, anhydrous lithium hydroxide (LiOH), lithium hydroxide monohydrate (LiOH-H 2 O), lithium chloride (LiCl), lithium chloride hydrate (LiCl-H 2 O), lithium carbonate (Li 2 CO 3 ), and lithium silicates.
- One or more precursors may be used in combination.
- the amount of lithium hydroxide in the absorbent formulation is calculated according to the type of precursor or precursors used in its preparation. If anhydrous lithium hydroxide is used in preparation, it is hydrated during processing to give lithium hydroxide monohydrate, which in turn will release lithium and hydroxide ions in the lime and water mixture.
- the present invention is further comprised of substances which improve processing and manufacturing properties, or which improve utilization efficacy or anesthetic compatibility.
- from about 0.1 to 5.0 % calcium chloride is present as a hurnectant.
- the absorbent formulation may further include 0.5 to 5.0 % glycerol as a humectant and as a chemical scavenger of the fluoro-olefin Compound A.
- the formulation of the invention may additionally comprise other minor components including an indicator dye, selected from ethyl violet, methyl violet, Titan yellow, Kenazol yellow, or Clayton yellow, present in the amount of 0.01 to 0.30 %.
- Hardening agents such as calcium chloride, magnesium chloride, aluminum silicate, lithium silicate, calcium sulfate, or magnesium sulfate may be present in the amount of 0.1 to 10%. From about 0.1 to 5.0% of alkali halides and/or alkaline earth halides can also be added as minor components.
- lithium silicate aqueous solution (containing 20 wt% lithium silicate) was mixed in 284 g water, followed by the addition of 31 g of glycerol. The resulting solution was then mixed with 1172 g of lime. In a separate container, 53 g of lithium hydroxide monohydrate was dissolved in 400 g water, followed by the addition of 15 mL of an aqueous ethyl violet indicator solution. The hydroxide solution was then mixed into the lime-silicate- glycerol mixture to the desired consistency and texture. The resulting paste was extruded to give cylindrical pellets approximately 3 mm in diameter and 3 to 10 mm in length. The pellets were oven dried at 110 °C to the preferred water content of about 15 wt%.
- lithium silicate aqueous solution (containing 20 % lithium silicate) was mixed in 284 g water, followed by the addition of 31 g of glycerol. The resulting solution was then added to 1184 g of lime and mixed to the desired consistency and texture. The resulting paste was extruded into pellets and dried to the desired water content.
- Examples 1-4 were tested in an anesthesia breathing circuit to measure carbon dioxide absorption performance and to monitor the formation of Compound A or other degradation byproducts.
- approximately 1 kg of absorbent was placed in the lower (downstream) absorbent canister of an anesthesia machine (North American Drager NARKOMED 2).
- a tidal volume of 500 mL was used at a breathing rate of 20 breaths per minute for a total volume of 10 liters per minute.
- the inspiratory: expiratory ratio was 1 :2.
- the sevoflurane concentration was set to 4% by volume (North American Drager Vaporizer 19.1).
- the fresh gas rate was 1 liter minute (600 mL N 2 O/400 mL O 2 ) to simulate low-flow anesthesia conditions.
- a CO 2 flow rate of approximately 400 mL per minute was delivered to an artificial lung to achieve 4% CO 2 in the expired gas.
- An ultrasonic bath was included in the lung assembly to achieve 100% relative humidity.
- Medical capnometers (DATASCOPE Multinex 4000) were used to monitor anesthesia circuit gases (sevoflurane, N 2 O, O 2 , CO 2 ) throughout the experiment: inspired gases coming from the absorbent canister (the inspiratory limb), and expired gases coming from the artificial lung (the expiratory limb).
- Carbon monoxide in the inspiratory limb was measured by sampling capnometer exhaust with a CO monitor (VULCAIN VA301D2). Gas samples were drawn from the inspiratory limb in order to monitor degradation by-products (such as Compound A) by gas chromatography. Each experiment was concluded when CO 2 gas concentration climbed to 0.5% by volume in the inspiratory limb of the breathing circuit.
- Example 1 summarizes the testing results for Examples 1-4, which comprise lithium hydroxide or one or more of its precursors.
- the amount of lithium hydroxide precursor or precursors in each formulation is given in weight percent, listed as the anhydrous species.
- the absorption performance of each sample is measured by its utilization: liters of carbon dioxide absorbed per kilogram of absorbent until exhaustion (0.5% CO 2 in the inspiratory limb), as determined by mass gain. TABLE 1. Examples of the Invention using LiOH Precursors
- Example (% as wt% of final product) 1 (ppm) (ppm) (L/kg)
- the balance of the formulations is lime and water.
- the utilization results in Table 1 demonstrate the similar performance of formulations prepared using different LiOH precursors. Samples prepared using lithium hydroxide monohydrate, lithium silicate, and lithium chloride absorb between 164-169 liters of carbon dioxide per kilogram of absorbent under low- flow anesthesia conditions. The addition of calcium chloride in the formulation as a humectant and hardening agent lowered the production of the sevoflurane degradation by-products compound A and carbon monoxide. Examples 3 and 4 were prepared in such a way so as to result in an identical absorbent composition of 0.1% lithium, 1.4% chlorine, 16% water, and 82.5% hydrated lime by weight. The degradation and utilization results in Table 1 further demonstrate the equivalence of using lithium hydroxide monohydrate and/or lithium chloride as precursors to lithium hydroxide in carbon dioxide absorbent formulations.
- the absorbent formulation comprises 70-90 wt% calcium hydroxide; 5-25 % water; 0.01-0.3 % ethyl violet as an indicator dye; 0.5 to 17 % LiCl as a lithium hydroxide precursor; and 0.1 to 5.0 % CaCl 2 as a humectant.
- Samples of the preferred formulation were prepared as Examples 5-8, and tested for pellet hardness, the production of sevoflurane degradation by-products, and carbon dioxide utilization. Experimental results for Examples 5-8, comprising LiCl as the lithium hydroxide precursor and CaCl 2 as a humectant, are given in Table 2.
- the formulation comprises: 0.025 % ethyl violet indicator; 0.5 % lithium chloride; 2.0 % calcium chloride; from 13-18 % water; and from 79-84 % lime; prepared as follows. Approximately 8 g of lithium chloride and 32 g of calcium chloride were dissolved in 923 g water, followed by the addition of approximately 15 mL of an aqueous ethyl violet indicator solution. The chloride solution was then mixed with 1288 g of lime; the resulting paste was then extruded into pellets, dried to the desired water content, and screened to give pellet sizes between about 0.2 and 0.5 cm in diameter.
- Example 9 Multiple samples of Example 9 were compared with commercial carbon dioxide absorbents in tests of absorption capacity and compatibility with anesthetic agents such as sevoflurane.
- Commercial absorbents included the following formulations shown in Table 3.
- Example 9 90 ⁇ 3 2 ⁇ 1 155 ⁇ 24 n.d. n.d.
- Example 9 produces much less compound A than samples of traditional absorbents which contain potassium hydroxide (Absorbent 1) or sodium hydroxide (Absorbent 2).
- the absorbent in Example 9 also has a greater carbon dioxide absorption capacity than commercial absorbents which contain calcium chloride (Absorbents 3 and 4), while maintaining good pellet hardness and minimal compound A production.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Environmental & Geological Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Gas Separation By Absorption (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treating Waste Gases (AREA)
- Carbon And Carbon Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007342521A AU2007342521B2 (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent |
KR20097011835A KR101492026B1 (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent |
MX2009006916A MX2009006916A (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent. |
EP07867769.7A EP2099560B1 (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent, a method of making it and a method of adsorbing carbon dioxide in anesthesia gas |
CA2672228A CA2672228C (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent |
JP2009544019A JP5368998B2 (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87721806P | 2006-12-26 | 2006-12-26 | |
US60/877,218 | 2006-12-26 | ||
US93303207P | 2007-06-04 | 2007-06-04 | |
US60/933,032 | 2007-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008085306A1 true WO2008085306A1 (en) | 2008-07-17 |
Family
ID=39608939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/025659 WO2008085306A1 (en) | 2006-12-26 | 2007-12-17 | Carbon dioxide absorbent |
Country Status (8)
Country | Link |
---|---|
US (1) | US7727309B2 (en) |
EP (1) | EP2099560B1 (en) |
JP (1) | JP5368998B2 (en) |
KR (1) | KR101492026B1 (en) |
AU (1) | AU2007342521B2 (en) |
CA (1) | CA2672228C (en) |
MX (1) | MX2009006916A (en) |
WO (1) | WO2008085306A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105214475A (en) * | 2014-05-30 | 2016-01-06 | 湖北航天化学技术研究所 | Carbon-dioxide absorbent of a kind of low flow resistance and preparation method thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8480516B2 (en) | 2011-02-23 | 2013-07-09 | Nike, Inc. | Methods for encouraging use of greenhouse gas reducing golf balls |
US8475297B2 (en) | 2011-02-23 | 2013-07-02 | Nike, Inc. | Golf ball with carbon dioxide absorbents |
PT106902A (en) | 2013-04-19 | 2014-10-20 | Carlos Alberto Mateus Afonso | ANESTHESIA CIRCUIT GAS PURIFICATION PROCESS USING MEMBRANE CONTACTORS |
RU2547483C1 (en) * | 2013-10-08 | 2015-04-10 | Открытое акционерное общество "Корпорация "Росхимзащита" (ОАО "Корпорация "Росхимзащита") | Method of producing carbon dioxide chemisorbent |
RU2685294C1 (en) * | 2018-05-10 | 2019-04-17 | Общество с ограниченной ответственностью "ДИНОН" (ООО "ДИНОН") | Absorbing compound, method for preparation thereof (versions) and method of removing carbon dioxide from gas mixtures |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3607040A (en) * | 1969-04-28 | 1971-09-21 | Universal Oil Prod Co | Preparation of alkali metal hydroxide pellets |
US6228150B1 (en) * | 1996-11-25 | 2001-05-08 | Armstrong Medical Limited | Carbon dioxide absorbent in anaesthesiology |
US20050160912A1 (en) * | 2004-01-28 | 2005-07-28 | Micropore, Inc. | Enhanced carbon dioxide adsorbent |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3489693A (en) * | 1967-04-03 | 1970-01-13 | Automatic Sprinkler Corp | Carbon dioxide absorbent |
US3847837A (en) * | 1972-04-25 | 1974-11-12 | Foote Mineral Co | Carbon dioxide absorbent granules |
JPS4951189A (en) * | 1972-09-19 | 1974-05-17 | ||
CA1151633A (en) * | 1981-05-27 | 1983-08-09 | Clive D. R. Macgregor | Absorption of carbon dioxide |
JP3571095B2 (en) * | 1995-02-02 | 2004-09-29 | 奥多摩工業株式会社 | Method for producing acid gas absorbent |
DE19740736A1 (en) | 1997-09-16 | 1999-03-18 | Foerster Harald Prof Dr | Respirator lime for use in anaesthetising apparatus |
EP1115482A1 (en) * | 1998-09-18 | 2001-07-18 | Förster, Harald | Calcium absorbent |
JP2000256010A (en) * | 1999-03-11 | 2000-09-19 | Idemitsu Petrochem Co Ltd | Recovering method of lithium |
DE19962141A1 (en) * | 1999-12-22 | 2001-07-12 | Chemetall Gmbh | Dry absorption process of CO¶2¶ in anesthesia machines |
GB0020656D0 (en) | 2000-08-23 | 2000-10-11 | Molecular Products Ltd | Improvements in or relating to carbon dioxide absorbent formulations |
JP2003088574A (en) * | 2001-09-19 | 2003-03-25 | Wako Pure Chem Ind Ltd | Novel acidic gas absorbent |
US6867165B2 (en) * | 2002-09-09 | 2005-03-15 | W. R. Grace & Co. -Conn. | Calcium hydroxide absorbent with rheology modifier and process involving same |
JP2006102561A (en) * | 2004-09-30 | 2006-04-20 | Toshiba Ceramics Co Ltd | Carbon dioxide absorption material and carbon dioxide reaction device |
-
2007
- 2007-12-17 MX MX2009006916A patent/MX2009006916A/en active IP Right Grant
- 2007-12-17 EP EP07867769.7A patent/EP2099560B1/en active Active
- 2007-12-17 US US12/002,449 patent/US7727309B2/en active Active
- 2007-12-17 JP JP2009544019A patent/JP5368998B2/en active Active
- 2007-12-17 CA CA2672228A patent/CA2672228C/en active Active
- 2007-12-17 AU AU2007342521A patent/AU2007342521B2/en active Active
- 2007-12-17 KR KR20097011835A patent/KR101492026B1/en active IP Right Grant
- 2007-12-17 WO PCT/US2007/025659 patent/WO2008085306A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3607040A (en) * | 1969-04-28 | 1971-09-21 | Universal Oil Prod Co | Preparation of alkali metal hydroxide pellets |
US6228150B1 (en) * | 1996-11-25 | 2001-05-08 | Armstrong Medical Limited | Carbon dioxide absorbent in anaesthesiology |
US20050160912A1 (en) * | 2004-01-28 | 2005-07-28 | Micropore, Inc. | Enhanced carbon dioxide adsorbent |
Non-Patent Citations (1)
Title |
---|
See also references of EP2099560A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105214475A (en) * | 2014-05-30 | 2016-01-06 | 湖北航天化学技术研究所 | Carbon-dioxide absorbent of a kind of low flow resistance and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2672228C (en) | 2015-02-03 |
AU2007342521B2 (en) | 2011-06-23 |
MX2009006916A (en) | 2009-07-06 |
US20080210091A1 (en) | 2008-09-04 |
CA2672228A1 (en) | 2008-07-17 |
AU2007342521A1 (en) | 2008-07-17 |
EP2099560B1 (en) | 2016-03-16 |
JP5368998B2 (en) | 2013-12-18 |
KR20090101172A (en) | 2009-09-24 |
US7727309B2 (en) | 2010-06-01 |
EP2099560A4 (en) | 2012-01-25 |
EP2099560A1 (en) | 2009-09-16 |
KR101492026B1 (en) | 2015-02-10 |
JP2010514556A (en) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2272933C (en) | Carbon dioxide absorbent in anaesthesiology | |
CA2672228C (en) | Carbon dioxide absorbent | |
CN101636225A (en) | Carbon-dioxide absorbent | |
JP2010514556A5 (en) | ||
EP1313555B1 (en) | Improvements in or relating to carbon dioxide absorbent formulations | |
CA2498170C (en) | Calcium hydroxide absorbent with rheology modifier and process involving same | |
JP4689417B2 (en) | Carbon dioxide absorbent | |
JP2008110278A (en) | Method for producing carbon dioxide absorbing agent | |
MX2011009913A (en) | Process for the manufacture of a material for absorbing dioxide carbon with a heat indicator. | |
RU2685294C1 (en) | Absorbing compound, method for preparation thereof (versions) and method of removing carbon dioxide from gas mixtures | |
BOZTAŞ | CARBON DIOXIDE ABSORBENTS | |
BRPI0305206B1 (en) | chemical composition to obtain c02-absorbing lime | |
JP2010155209A (en) | Carbon dioxide absorbent and method of manufacturing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780047924.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07867769 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007342521 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2139/KOLNP/2009 Country of ref document: IN Ref document number: 1020097011835 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2672228 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/006916 Country of ref document: MX Ref document number: 2007867769 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009544019 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007342521 Country of ref document: AU Date of ref document: 20071217 Kind code of ref document: A |